“Can Rare Cancer Drugs Expect Sales in Japan?: A Prescription Pattern Analysis of Drugs for Chronic Myelogenous Leukemia and Neuroendocrine Tumor” (2019) Journal of Regulatory Science, 7, pp. 1–9. doi:10.21423/JRS-V07SHIBATA.